RADNOR, Pa. (AP) — RADNOR, Pa. (AP) — Marinus Pharmaceuticals Inc. (MRNS) on Tuesday reported a loss of $41.8 million in its fourth quarter.
The Radnor, Pennsylvania-based company said it had a loss of 74 cents per share.
The results did not meet Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 64 cents per share.
The epilepsy drug developer posted revenue of $7.2 million in the period, also falling short of Street forecasts. Five analysts surveyed by Zacks expected $7.8 million.
For the year, the company reported a loss of $141.4 million, or $2.63 per share. Revenue was reported as $31 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MRNS at https://www.zacks.com/ap/MRNS